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Nucleotide-binding oligomerization domain leucine rich repeat and pyrin domain-
containing protein 3 (NLRP3) inflammasome is pivotal in maintaining intestinal
homeostasis and sustaining enteric immune responses in the setting of inflammatory
bowel diseases. Drugs acting as NLRP3 blockers could represent innovative
strategies for treatment of bowel inflammation. This study was performed in rats
with dinitrobenzenesulfonic acid (DNBS)-induced colitis, to investigate how the direct
blockade of NLRP3 inflammasome with an irreversible inhibitor (INF39) compares with
Ac-YVAD-cmk (YVAD, caspase-1 inhibitor) and anakinra (IL-1β receptor antagonist),
acting downstream on NLRP3 signaling. Animals with DNBS-colitis received YVAD
(3 mg/kg) or anakinra (100 mg/Kg) intraperitoneally, and INF39 (25 mg/kg) or
dexamethasone (DEX, 1 mg/kg) orally for 6 days, starting on the same day of colitis
induction. Under colitis, there was a body weight decrease, which was attenuated by
YVAD, anakinra or INF39, but not DEX. All test drugs counteracted the increase in
spleen weight. The colonic shortening and morphological colonic alterations associated
with colitis were counteracted by INF39, anakinra and DEX, while YVAD was without
effects. Tissue increments of myeloperoxidase, tumor necrosis factor and interleukin-1β
were more effectively counteracted by INF39 and DEX, than YVAD and anakinra. These
findings indicate that: (1) direct inhibition of NLRP3 inflammasome with INF39 is more
effective than caspase-1 inhibition or IL-1β receptor blockade in reducing systemic and
bowel inflammatory alterations; (2) direct NLRP3 inhibition can be a suitable strategy for
treatment of bowel inflammation.
Keywords: anakinra, caspase-1, colitis, colon, NLRP3 inflammasome, interleukin-1beta, bowel inflammation
Abbreviations: DEX, dexamethasone; DMSO, dimethyl sulfoxide; DNBS, 2,4-dinitrobenzenesulfonic acid; IL-1β,
interleukin-1beta; MPO, myeloperoxidase; NF-κB, nuclear factor-κB; NLRP3, nucleotide-binding oligomerization domain
leucine rich repeat and pyrin domain-containing protein 3; TNF, tumor necrosis factor.
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INTRODUCTION
Inflammatory bowel diseases (IBDs), including Crohn’s
disease and ulcerative colitis, are chronic relapsing disorders
characterized by inflammation and tissue damage in the digestive
tract (Neurath, 2014). Such diseases are associated with marked
morbidity and have a remarkable negative impact on patients’
quality of life, which highlights the need for setting up novel
anti-inflammatory therapeutic strategies (Blonski et al., 2011).
Recent studies have shown that the nucleotide-binding
oligomerization domain, leucine-rich repeat and pyrin domain
containing protein 3 (NLRP3) inflammasome cytosolic
complex, besides acting as a key player in the maintenance
of intestinal homeostasis, shapes innate immune responses
against commensal bacteria. Indeed, NLRP3 over-activation
during bowel inflammation is associated with a breakdown of
enteric immune balance, suggesting an involvement of NLRP3
in the pathogenesis of bowel inflammation (Bauer et al., 2010;
Kanneganti, 2017; Pellegrini et al., 2017b).
The activation of NLRP3 inflammasome requires two
parallel and independent steps: transcription and oligomerization
(Martín-Sanchez et al., 2016; Gaidt and Hornung, 2018; Mangan
et al., 2018). The first step is regulated by innate immune
signaling, mediated primarily by toll-like receptors (TLRs),
myeloid differentiation primary response 88 (MyD88) and/or
cytokine receptors, such as TNF receptor, which, in turn, activate
pro-IL-1β and NLRP3 transcription via NF-κB activation. The
second step results in NLRP3 inflammasome oligomerization,
leading to caspase-1 activation and, in turn, IL-1β and IL-18
processing and release (Sutterwala et al., 2014).
Of note, clinical evidence has documented an increase in
IL-1β release from colonic tissues and macrophages of IBD
patients, these patterns being correlated with disease severity,
thus suggesting IL-1β as a relevant pro-inflammatory cytokine
involved in the pathophysiology of IBDs (Coccia et al., 2012).
Given the involvement of the inflammasome pathway in the
pathophysiology of intestinal inflammation, current research
efforts are being focused on the potential therapeutic benefits
resulting from the pharmacological modulation of NLRP3
inflammasome. In this respect, previous studies investigated the
role of NLRP3 inflammasome in several experimental models
of colitis, highlighting remarkable beneficial effects as a results
of its pharmacological modulation (Pellegrini et al., 2017b). For
instance, two recent studies showed that both the in vivo caspase-
1 inhibition and the selective blockade of NLRP3 inflammasome
complex significantly attenuated colonic inflammation in
spontaneous colitis mice (Zhang et al., 2014; Perera et al., 2018).
In addition, Stoffels et al. (2014) reported that anakinra reduced
post-operative inflammation and ameliorated post-operative
ileus in mice, thus suggesting that IL-1β receptor blockade exerts
beneficial effects during intestinal inflammation (Stoffels et al.,
2014). Moreover, in a recent paper, we observed that the in vivo
direct irreversible inhibition of NLRP3 with INF39, a novel
acrylate compound able to inhibit NLRP3 ATPase activity, exerts
beneficial effects on bowel inflammation (Cocco et al., 2017).
These findings suggest that both upstream and downstream
inhibition of NLRP3 inflammasome could represent suitable
pharmacological approaches to the treatment of bowel
inflammation. However, a direct comparative study on the
efficacy of NLRP3 inflammasome signaling inhibitors in a
pre-clinical model of bowel inflammation is lacking.
Based on this background, the present study was designed
to investigate how the direct blockade of NLRP3 with INF39 in
experimental colitis compares, in terms of efficacy, with other
drugs acting downstream (caspase-1 inhibition or IL-1β receptor
blockade) on NLRP3 signaling.
MATERIALS AND METHODS
Animals
Experimental procedures were performed on male Sprague-
Dawley rats, 200–250 g body weight. The animals received
standard laboratory chow and tap water without any restriction
and were housed, three in a cage, in temperature- controlled
rooms on a 12-h light cycle at 22–24◦C and 50–60% humidity.
Animal care and handling were in accordance with the
provisions of the European Community Council Directive
2010/63/UE, recognized and adopted by the Italian Government.
All experimental procedures were approved by the Ethical
Committee for Animal Experimentation of the University of Pisa
and by the Italian Ministry of Health (authorization n◦ 674/2016-
PR). In the present study, animal data have been presented
according to the ARRIVE guidelines.
Induction of Colitis and Drug Treatments
Colitis was induced in accordance with the method described
previously (Antonioli et al., 2010). The subsequent experimental
procedures were performed 6 days after DNBS administration
to allow a full development of colonic inflammation. Rats were
subjected to administration of the test drugs by intragastric
or intraperitoneal (i.p.) route for 6 days, starting on the
same day of DNBS injection. DNBS-untreated (controls)
and DNBS-treated animals were treated as follows: INF39
(25 mg/kg/day, oral), Ac-YVAD-cmk (YVAD, caspase-
1 inhibitor, 3 mg/Kg/day, i.p.), anakinra (IL-1β receptor
antagonist, 100 mg/Kg/day i.p.) or DEX (active comparator,
1 mg/kg/day, oral). INF39 and DEX were suspended in olive
oil and 1% methylcellulose, respectively. YVAD was dissolved
in sterile DMSO, and further dilutions were made with sterile
saline.
Subgroups of DNBS-untreated and DNBS-treated rats
received drug vehicles to serve as controls. Body weight was
assessed daily, starting from the onset of drug administrations.
The doses of INF39 and DEX were selected on the basis of
our previous study performed on the same rat model of colitis
(Cocco et al., 2017).
The doses of YVAD and anakinra were selected on
the basis of previous studies performed in rat models of
diabetes induced by stress or in streptozotocin, respectively
(Maslanik et al., 2013; Vallejo et al., 2014), and by preliminary
experiments designed to test increasing doses of both compounds
(YVAD, 0.75, 1.5, 3, and 6 mg/kg; anakinra, 25, 50, 100,
and 200 mg/Kg ) on colonic MPO levels in the model
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of DNBS-induced colitis. Macroscopic and histological scores
were assessed on the whole colon, while biochemical assays
were performed on colonic segments collected from an
inflamed region adjacent and distal to the gross necrotic
damage.
Assessment of Colitis
Colonic tissues were scored for macroscopic and histological
damage, as reported previously (Antonioli et al., 2010; Cocco
et al., 2017). The criteria for macroscopic scoring of colonic
damage were as follows: (1) presence of adhesions between
colonic tissue and other organs (0, none; 1, minor; 2, major
adhesions); (2) consistency of colonic fecal material (0, formed;
1, loose; 2, liquid stools); and (3) presence of ulceration (0, none;
1, hyperemia; 2, ulceration without hyperemia; 3, ulceration
with inflammation at one side; 4, ≥ 2 sites of ulceration and
inflammation; 5, major sites of damage; and 6, major sites
of damage extending > 2 cm). The score was then increased
by one unit for each millimeter of colonic wall thickness.
Microscopic damage and inflammation were assessed by light
microscopy on hematoxylin/eosin-stained histological sections
obtained from whole gut specimens. The histological criteria
included mucosal architecture loss (0 –3), cellular infiltrate (0 –
3), muscle thickening (0 –3), crypt abscess (0, absent; 1, present),
and goblet cell depletion (0, absent; 1, present). All parameters of
macroscopic and histological damages were recorded and scored
for each rat by two observers blinded to the treatment. At the time
of experiment, the weight of spleen and the colonic length were
also measured.
Evaluation of Tissue Myeloperoxidase
Levels
The evaluation of MPO levels, regarded as quantitative index
for quantification of the degree of intestinal tissue infiltration by
polymorphonuclear cells, was performed as described previously
(Fornai et al., 2016). Colonic samples (30 mg) were put in
0.6 ml of ice-cold lysis buffer containing 200 mM NaCl, 5 mM
EDTA, 10 mM Tris, 10% glycerine, 1 mM phenylmethylsulfonyl
fluoride, 1 g/ml leupeptin and 28 g/ml aprotinin (pH 7.4) and
homogenized on ice with a polytron homogenizer (QIAGEN,
Milan, Italy). After centrifugation (2 times at 4◦C for 15 min
at 1,500g), the supernatant was diluted 1:5 and used for MPO
concentration assessment by an enzyme-linked immunosorbent
assay (ELISA) (Hycult Biotech, Uden, Netherlands). Data were
expressed as nanograms of MPO per milligram of colonic tissue.
Evaluation of Tissue TNF and IL-1β
Levels
The evaluation of TNF and IL-1β levels in colonic tissues was
performed by an ELISA kit (Abcam), as described previously by
Pellegrini et al. (2017a). Briefly, colonic samples, were weighed
and homogenized in 0.4 ml of PBS, pH 7.2/20 mg of tissue at
4◦C, and centrifuged at 10,000g for 5 min. Supernatants were
employed for the assay. The concentrations of TNF and IL-1β
were expressed as picograms and nanograms per milligram of
tissue, respectively.
Drugs and Reagents
Dimethyl sulfoxide, DNBS, DEX, Ac-YVAD-cmk
(caspase-1 inhibitor) and methylcellulose were purchased
from Sigma-Aldrich (St. Louis, MO). The synthesis of INF39
was performed as previously reported (Cocco et al., 2014, 2016,
2017). Anakinra was purchased from Sobi, Swedish Orphan
Biovitrum s.r.l. (Parma, Italy).
STATISTICAL ANALYSIS
The results are presented as mean ± S.E.M. unless otherwise
stated. Data have been reported also synoptically in Table 1
as percent changes against the values estimated in animals
with colitis for the purpose of support to the discussion. The
significance of differences was evaluated on raw data by one-
way analysis of variance followed by post hoc analysis with
Student-Newman-Keuls test. P-values < 0.05 were considered
significantly different. All statistical procedures were performed
by a commercial software (GraphPad Prism, version 7.0 from
GraphPad Software Inc., San Diego, CA, United States).
RESULTS
Body Weight, Spleen Weight and Colonic
Length
The administration of INF39, YVAD, anakinra and DEX to
animals treated with DNBS vehicle did not elicit any significant
change in both systemic and tissue parameters (data not shown).
On this basis, we adopted the animals treated with DNBS vehicle
rats as control group for all the evaluations on the drugs under
investigation, collectively designed as test drugs.
Six days after administration of the DNBS vehicle, control
rats showed a weight gain of 19.6 ± 0.9 g, while rats treated
TABLE 1 | Synoptic presentation of percent changes of tissue-related inflammatory parameters in DNBS-rats treated with YVAD, anakinra, INF39 or DEX against values
estimated in animals with colitis.
Colon length Macroscopic damage score Microscopic damage score MPO TNF IL-1β
YVAD + 7.6 −38.1 −37.7 −61.5 +18.5 −32.4
Anakinra + 20.1 −55.1 −50.9 −66.7 + 4.5 −12.6
INF39 + 22.1 −62.8 −67.8 −83.4 −50.5 −65.5
DEX + 18.4 −71.8 −73.5 −90.1 −57.4 −76.3
DEX, Dexamethasone; DNBS, 2,4-dinitrobenzenesulfonic acid; TNF, tumor necrosis factor; IL-lβ, interleukin-l beta; MPO:myeloperoxidase.
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with DNBS displayed a decrease of 36.6 ± 4.4 g in their body
weight. In rats with colitis, treatment with YVAD, anakinra and
INF39 significantly attenuated the body weight loss, while DEX
promoted a further, although not significant, decrease in body
weight. In this respect, it is widely recognized that steroid therapy
is associated with several systemic adverse effects, including
muscular atrophy, with consequent loss of body weight (De
Cassan et al., 2012).
Of note, INF39 was significantly more effective in blunting
body weight loss, as compared with anakinra (Figure 1),
suggesting that the upstream inhibition of NLRP3 activation is
more effective than the downstream IL-1β receptor blockade.
Spleen weight was taken as an index of systemic inflammation
(Chassaing et al., 2014) (Siegmund et al., 2001). Treatment
with DNBS resulted in a significant increment of spleen weight
(+44.3%), as compared with control animals. Such an increase
was significantly counteracted to a similar extent by YVAD,
anakinra and INF39 (Figure 1B).
Six days after DNBS administration, inflamed rats were
characterized by a shortening of colonic length (−37.2%), as
compared with control animals. Treatment of inflamed rats with
anakinra, DEX or INF39 attenuated significantly the decrease
in colonic length, while YVAD did not exert significant effects;
(Figure 2A and Table 1), suggesting that both the upstream
and downstream inhibition of NLRP3 signaling with INF39 and
FIGURE 1 | Effects of Ac-YVAD-cmk (YVAD, 3 mg/Kg), anakinra (100 mg/Kg),
INF39 (25 mg/kg) or DEX (1 mg/kg) on body weight gain/loss (A) and spleen
weight changes (B), at day 6 after induction of colitis with DNBS. Each
column represents the mean ± S.E.M. (n = 10). ∗P < 0.05, significant
difference vs. control group; aP < 0.05, significant difference vs. DNBS group.
FIGURE 2 | Colonic length changes (A) and macroscopic damage score
(B) in rats under normal conditions or with DNBS-induced colitis, either alone
or after treatment with Ac-YVAD-cmk (YVAD, 3 mg/Kg), anakinra
(100 mg/Kg), INF39 (25 mg/kg) or DEX (1 mg/kg). Each column represents
the mean ± S.E.M. (n = 10). ∗P < 0.05, significant difference vs. control
group; aP < 0.05, significant difference vs. DNBS group.
anakinra, respectively, is more effective than caspase-1 inhibition
in counteracting the decrease in colonic length.
Macroscopic Damage
The administration of DNBS was associated with colonic
thickening and ulcerations, with marked areas of transmural
inflammation. In addition, adhesions and bowel dilations were
detected, with a macroscopic damage accounting for 7.8 ± 0.6.
In this setting, the macroscopic damage was reduced to a similar
extent and significantly by anakinra, INF39 and DEX, while the
effect of YVAD did not achieve statistical significance; anakinra
and INF39 acted with similar efficacy (Figure 2B and Table 1).
Microscopic Damage
Microscopic evaluation of colonic tissues revealed the presence of
large areas of mucosal necrosis in animals treated with DNBS, as
well as the destruction of glandular architecture.
The submucosa appeared thickened due to the presence
of edema and inflammatory cell infiltration. The underlying
muscular layer appeared also thickened and infiltrated with
inflammatory cells following DNBS administration. The mucosa
and submucosa surrounding the necrotic area displayed
inflammation associated with marked cellular infiltration, as
compared with tissues from control animals (Figure 3A).
In colonic tissues from inflamed rats, the microscopic score
was significantly increased in comparison with control animals
(5.3 ± 0.4 vs. 1.4 ± 0.1, respectively). When treated with
anakinra, INF39 and DEX, animals with colitis displayed similar
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FIGURE 3 | (A) Hematoxylin and eosin-stained sections of rat colon.
Representative microscopic images refer to control rats or animals with colitis
induced by DNBS. (B) Microscopic damage score estimated for colon in rats
under normal conditions or with DNBS-induced colitis, either alone or after
treatment with Ac-YVAD-cmk (YVAD, 3 mg/Kg), anakinra (100 mg/Kg), INF39
(25 mg/kg) or DEX (1 mg/kg). Each column represents the mean ± S.E.M.
(n = 10). ∗P < 0.05, significant difference vs. control group; aP < 0.05,
significant difference vs. DNBS group.
and significant reductions of the microscopic damage, while the
effect of YVAD did not achieve the level of statistical significance
(Figure 3B and Table 1).
MPO Levels in Colonic Tissues
Rats with DNBS-induced colitis showed a marked increase in
colonic MPO levels (56.3 ± 4.9 ng/mg tissue), as compared with
control animals (3.2 ± 1.1 ng/mg tissue). Treatment with all test
drugs prevented significantly the increments of colonic MPO
levels associated with DNBS administration, with INF39 being
more effective than YVAD and anakinra (Figure 4A and Table 1).
TNF Levels in Colonic Tissues
Colonic inflammation induced by DNBS was associated with
a significant increase in tissue TNF levels (7.1 ± 1.2 pg/mg
tissue), as compared with values obtained in control animals
(2.7 ± 0.2 pg/mg tissue). Treatment with INF39 or DEX
decreased significantly the concentration of this cytokine in
FIGURE 4 | Myeloperoxidase (MPO) (A), tumor necrosis factor (TNF) (B) and
interleukin-1β (IL-1β) (C) levels in colonic tissues from control rats or animals
with DNBS-induced colitis, either alone or after treatment with Ac-YVAD-cmk
(YVAD, 3 mg/Kg), anakinra (100 mg/Kg), INF39 (25 mg/kg) or DEX (1 mg/kg).
Each column represents the mean ± S.E.M. (n = 10). ∗P < 0.05, significant
difference vs. control group; aP < 0.05, significant difference vs. DNBS group.
colonic tissues, while YVAD and anakinra were without effects
(Figure 4B and Table 1).
IL-1β Levels in Colonic Tissues
Rats with colitis displayed a significant increase in colonic IL-
1β levels (27.7 ± 4.2 ng/mg tissue), as compared with values
estimated in control animals (9.2± 0.9 ng/mg tissue). Treatment
with YVAD, INF39 and DEX was associated with a significant
decrease in IL-1β levels; INF39 was more effective than YVAD.
Anakinra was without effects (Figure 4C and Table 1).
DISCUSSION
The involvement of inflammasome pathways in the
pathophysiology of intestinal inflammation is fostering research
about the potential therapeutic benefits, in terms of anti-
inflammatory activity, resulting from the pharmacological
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modulation of NLRP3 inflammasome. Nowadays, the majority
of available studies have investigated the role of NLRP3 in several
experimental models of colitis, highlighting remarkable beneficial
effects associated with the pharmacological modulation of this
enzymatic complex (Pellegrini et al., 2017b). In particular, the
most investigated strategies, aimed at validating and developing
novel pharmacological entities targeting NLRP3 signaling,
have been: (i) inhibition of the activation of the transcription
factor NF-κB; (ii) protection against mitochondrial damage;
(iii) activation of the Keap-1/Nrf2 antioxidant pathway; (iv)
inhibition of pro-caspase-1 cleavage through undetermined
interactions with NLRP3 inflammasome; and (v) blockade of
IL-1β receptor (Sutterwala et al., 2014; Cocco et al., 2017; Perera
et al., 2017). However, at present, there is a lack of suitable drug
candidates able to directly and selectively inhibit the NLRP3
ATPase activity. This represents an intriguing issue, since the
development of drugs endowed with direct inhibitory effects on
NLRP3 are expected to ensure a more efficient control of several
NLRP3-dependent downstream signals, pivotally involved in the
regulation of immune/inflammatory processes (Pellegrini et al.,
2017b).
The above background was taken as a rationale for the
development of INF39, an acrylate compound, able to block
selectively and irreversibly the NLRP3 ATPase activity (Cocco
et al., 2017). In vitro studies showed that INF39 counteracted
significantly NLRP3 activation through a direct and irreversible
interaction with the enzyme complex (Cocco et al., 2017). The
impact of a direct NLRP3 blockade on bowel inflammation was
then tested in a murine model of DNBS-induced colitis (Cocco
et al., 2017). In this setting, INF39 exerted significant beneficial
effects, alleviating both the systemic and tissue inflammatory
outcomes of colitis, and showing also a satisfactory safety profile
(Cocco et al., 2017).
In the present study, our specific purpose was to compare
the efficacy of INF39 with other drugs, acting downstream on
the NLRP3 signaling (i.e., caspase-1 inhibition or IL-1β receptor
blockade), in an experimental model of bowel inflammation.
To pursue this goal, we employed rats with DNBS-induced
colitis, which match closely the patterns of Crohn’s disease in
humans, and are characterized by body weight loss, diarrhea,
ulceration and bleeding, depletion of goblet cells and formation
of granulomas within the colonic wall (Goyal et al., 2014).
The model of DNBS-induced colitis is a suitable tool for the
investigation of the anti-inflammatory activity of novel drugs
with potential therapeutic efficacy in human bowel inflammatory
disorders (Esposito et al., 2010). The appropriateness of this
model was previously validated by our research group. Indeed,
we confirmed DEX was able to ameliorate systemic and
tissue inflammatory parameters, as also previously described by
Antonioli et al. (2010).
Overall, our results provide convincing evidence that the
pharmacological modulation of the NLRP3 inflammasome
pathway attenuates bowel inflammation in DNBS-induced colitis,
and that direct NLRP3 inhibition by INF39 is more effective
than caspase-1 inhibition by YVAD or IL-1β receptor blockade
by anakinra in controlling several parameters associated with
intestinal inflammation. When considering the systemic indexes
of inflammation, treatment with INF39, YVAD and anakinra
counteracted the body weight loss and the increment of spleen
weight in DNBS-rats. In addition, the inhibitors of NLRP3
signaling did not exert detrimental effects on body weight,
at variance with DEX, which, being a systemically acting
glucocorticoid derivative, is known to be associated with a
variety of adverse effects, including muscular atrophy (De
Cassan et al., 2012). When analyzing colonic length and bowel
morphological parameters, INF39 and anakinra counteracted
significantly the colonic shortening and improved both the
macroscopic and histological features of colitis, as compared with
YVAD, thus suggesting that the direct inhibition of NLRP3 or
IL-1β receptor blockade can exert significant beneficial effects
on tissue parameters related to inflammation than caspase-1
inhibition. Of note, when considering body weight and colonic
length, we observed heterogeneous effects of the drugs under
investigation. In this respect, it is noteworthy that body weight
and colonic length in animals with colitis, despite being widely
employed, are colonic coarse parameters, which can be associated
also with high variability, as compared with the assessment of
colonic microscopic damage or colonic MPO, TNF and IL-1β
levels (see below). This is a relevant point since, when testing the
effects of drugs on coarse parameters the net effect of individual
drugs could be less evident. As a consequence, this circumstance
might explain why anakinra was less effective than INF39 in
attenuating body weight, or why YVAD did not exert a significant
effect on colonic length.
Taken together, the present findings are in line with recent
studies showing that treatment with MCC950, a potent and
highly specific small molecule inhibitor of NLRP3 inflammasome
counteracted bowel inflammation in a spontaneous colitis
murine model (Winnie mice), and, that anakinra reduced post-
operative inflammation and ameliorated post-operative ileus in
mice (Stoffels et al., 2014; Perera et al., 2018). In addition,
two recent studies showed that a synthetic benzimidazole
compound and fumigaclavine C, a fungal metabolite exerted anti-
inflammatory effects in mice with colitis induced by dextran
sulfate sodium (DSS), through the inhibition of caspase-1
activation (Liu et al., 2013; Guo et al., 2015). However, although
both compounds were able to inhibit caspase-1 activation, they
influenced also other intracellular pathways, including MAPK,
STAT1 and NF-κB signaling. Therefore, their anti-inflammatory
effects on colitis may not result merely from the inhibition of
caspase-1.
A variety of inflammatory mediators have been shown to take
a significant part in the pathogenesis of bowel inflammation
(Neurath, 2014). In particular, it is recognized that TNF plays
a pivotal role, both in humans and experimental colitis models
in the production of chemoattractants for neutrophils and
their activation. Activated neutrophils infiltrate the mucosa and
submucosa, and contribute to intestinal injury through a number
of mechanisms (Neurath, 2014). This body of knowledge explains
why anti-cytokine therapies based on TNF-specific blocking
agents represent an important cornerstone of medical therapy in
both Crohn’s disease and ulcerative colitis (Danese and Fiocchi,
2011; Baumgart and Sandborn, 2012). Taking this rationale into
account, we examined the effects of all test drugs on the colonic
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levels of TNF and MPO (a quantitative index reflecting the degree
of colonic infiltration by polymorphonuclear cells) in DNBS-rats.
Interestingly, our results showed that INF39, but not YVAD and
anakinra, counteracted significantly the increments of TNF, and
that INF39 blunted the increased MPO levels with greater efficacy
than the caspase-1 inhibitor and IL-1β receptor antagonist in
rats with colitis, thus corroborating the concept that the direct
blockade of NLRP3 could represent a better pharmacological
strategy for treatment of bowel inflammation, than caspase-1
inhibition and IL-1β receptor blockade (Pellegrini et al., 2017b).
The above results are in line with a recent study showing that
treatment of animals with spontaneous chronic colitis (Winnie
mice) with a specific NLRP3 inhibitor (MCC950) counteracted
bowel inflammation, improving both the macroscopic and
histological features of colitis and reducing significantly the
release of pro-inflammatory cytokines, including TNF levels
(Perera et al., 2018).
Of note, the peculiar effect of INF39 in downregulating TNF
tissue levels depends very likely on its ability to modulate TNF
gene expression. Indeed, as observed in our previous study,
the exposure of bone marrow-derived macrophages, stimulated
with lipopolysaccharide, to INF39 was followed by a significant
decrease in TNF gene expression, as compared with INF39-
untreated cells (Cocco et al., 2017).
Several lines of pre-clinical and clinical evidence point out
a key role of IL-1β in the pathophysiology of IBDs (Neurath,
2014). Indeed, colonic tissues and lamina propria macrophages
from IBD patients showed an increased IL-1β secretion, this
activity being well correlated with disease severity (Gustot et al.,
2005; Coccia et al., 2012). A significant activation of NLRP3
inflammasome, with a consequent massive release of IL-1β, has
been detected previously in monocytes infiltrating the lamina
propria and M1 pro-inflammatory macrophages isolated from
intestinal specimens of IBD patients (Lissner et al., 2015). For this
reason in the present study, sets of experiments were devoted to
evaluate the efficacy of test drugs in counteracting IL-1β release.
In this setting, treatment with INF39 was more effective than
anakinra and YVAD in counteracting the increase in IL-1β levels
in colonic tissues from DNBS-rats. Anakinra, being a receptor
blocker, was not expected indeed to modify IL-1β release.
Furthermore, even though anakinra is currently employed for
treatment of some immune-mediated inflammatory diseases (i.e.,
rheumatoid arthritis, ankylosing spondylitis and gout) (Dinarello
et al., 2012), scarce beneficial effects of this drug were observed
in patients with IBDs, thus indicating the selective blockade of
IL-1β receptor as a loosing strategy for the management of such
diseases (Carter et al., 2003; Hügle et al., 2017). Indeed, although
several pre-clinical studies in animal models of colitis showed
that the inhibition of IL-1β decreased tissue inflammation and
necrosis, others found few or no beneficial effects following IL-1β
inhibition (de Mooij et al., 2017). In addition, in a previous study,
Carter et al. (2003) reported that the administration of anakinra
to patients with Crohn’s disease was associated with a worsening
of clinical conditions, including fever, increased diarrhea and
abdominal pain.
When considering the caspase-1 blocker YVAD, recent studies
have shown that, besides caspase-1, a non-canonical NLRP3
inflammasome activation, which depends on caspase-11, plays a
significant role also both in the maintenance of intestinal immune
homeostasis and in sustaining the pathophysiological events that
underlie bowel inflammation (Kayagaki et al., 2011; Vigano and
Mortellaro, 2013). In particular, caspase-11 overactivation during
bowel inflammation contributes to the massive release of IL-
1β through activation of the NLRP3-ASC-caspase-1 pathway,
and the inhibition of both canonical and non-canonical caspase-
11-dependent NLRP3 activation has been found to exert anti-
inflammatory effects on colitis in mice (Márquez-Flores et al.,
2016). Other studies on murine bone marrow-derived dendritic
cells (BMDCs) have shown that, besides canonical and non-
canonical caspase-11-dependent NLRP3 activation, a caspase-8-
dependent NLRP3 inflammasome activation can be called into
play also to promote the processing and release of IL-1β. Indeed,
IL-1β processing and caspase-8 activation were not evident in
Nlrp3−/−or Asc−/− BMDCs, thus indicating that caspase-8 can
act as a direct IL-1β-converting enzyme (Antonopoulos et al.,
2015;Chung et al., 2016). Moreover, Gringhuis et al. (2012)
showed that the release of IL-1β from dendritic cells, stimulated
with a fungal infection, occurred independently of caspase-1, but
required an association of the inflammasome protein ASC with
caspase-8. Based on these observations, it is conceivable that,
in our experiments, INF39, through the specific inhibition of
NLRP3 ATPase activity, ensured a blockade of both canonical
and non-canonical caspase-8- and caspase-11-dependent NLRP3
activation, thus leading to a more effective blockade of IL-1β
release, as compared with YVAD. Of interest, our results are
consistent with the findings of a recent study, showing that the
direct and selective blockade of inflammasome with MCC950, the
FIGURE 5 | Diagram showing the molecular mechanisms through which test
drugs may inhibit NLRP3 signaling and counteract intestinal inflammation.
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most specific and well characterized NLRP3 inhibitor available so
far, attenuated colonic inflammation in mice with spontaneous
colitis, likely through the inhibition of both canonical and
non-canonical NLRP3 activation (Perera et al., 2018). However,
the possible role and respective significance of non-canonical
caspase-8- and caspase-11-dependent NLRP3 activation in the
pathophysiology of bowel inflammation requires confirmation by
means of specific experimental approaches. In addition, further
studies are needed to evaluate the effects of in vivo selective
blockade of non-canonical caspase-8- and caspase-11-dependent
NLRP3 activation in animal models of colitis.
Of note, given the pivotal role of NLRP3 in regulating
the integrity of intestinal homeostasis, the possibility that its
pharmacological blockade during bowel inflammation could
interfere with healing processes should be taken into account. In
this respect, several lines of evidence have shown that, in the early
acute phases of inflammation, NLRP3 inflammasome activation
contributes to tissue repair and maintenance of epithelial
barrier integrity, while in the later chronic phase of colitis, the
overactivation of NLRP3 promotes the differentiation of T cells
into effector Th1 and Th17 phenotypes, which contribute to
sustain the inflammatory response. In line with this concept, the
pharmacological inhibition of NLRP3 inflammasome signaling
has been shown to exert beneficial effects in several experimental
models of colitis (Pellegrini et al., 2017b). However, the possibility
that long-term treatments with NLRP3 inhibitors could interfere
with mucosal healing cannot be ruled out and deserves further
investigations.
CONCLUSION
In conclusion, our results expand current knowledge on the
beneficial effects arising from the pharmacological modulation of
NLRP3 inflammasome in experimental colitis (Pellegrini et al.,
2017b), suggesting that the direct and irreversible inhibition of
NLRP3 inflammasome complex could represent a more viable
approach to the medical management of bowel inflammation
than IL-1β receptor blockade or caspase-1 inhibition (see
Figure 5). In keeping with this perspective, INF39 might
represent a lead compound for the identification of novel
NLRP3 inhibitors, characterized by high degrees of efficacy and
concomitant favorable safety profiles. Therefore, the present
observations might pave the way to the design and clinical
development of novel NLRP3 selective inhibitors for the
therapeutic management of patients with IBDs.
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